{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Duration of response based on the Myeloma response determination criteria developed by Bladé et al 1998 and defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on International Myeloma Working Group (IMWG) criteria.","groups":[{"description":"Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle","id":"OG000","title":"Lenalidomide 25mg"}],"populationDescription":"Duration of response not analyzed per the sponsors decision.","reportingStatus":"POSTED","timeFrame":"Up to 70 months","title":"Duration of Response","type":"SECONDARY"}